Therefore, it is reasonable to assume that administration of MG132 and deguelin may constitute a new molecular basis for the inhibition of inflammatory activation in rats with diabetic nephropathy by interruption of activated Akt. The gene discussed is AKT1; the disease is diabetic kidney disease.